Navigation Links
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
Date:2/5/2009

on (57.4%), asthenia (51.8%) and nausea (50%). Only two patients went off study due to "dermatitis".

About Myocet(TM) (Nonpegylated Liposomal Doxorubicin)

Myocet is a liposome-encapsulated doxorubicin-citrate complex. By encapsulating doxorubicin in a liposome - a manufactured, microscopic, vesicle consisting of discreet aqueous compartments surrounded by membranes composed of naturally occurring fats - its distribution in the body is altered in such a way as to reduce doxorubicin's toxicity. Extensive clinical studies of Myocet in women with breast cancer have shown that the cardiac toxicity of doxorubicin can be significantly reduced, while the efficacy of the drug is maintained. This delivery system does not encompass pegylation and yields very little hand foot syndrome.

The results of the SOLTI study further support an ongoing registration trial in patients with metastatic HER-2-overexpressing breast cancer, sponsored by Sopherion Therapeutics, LLC. This is a pivotal Phase III trial of Myocet(TM), paclitaxel and trastuzumab vs. paclitaxel and trastuzumab that uses progression-free survival as the primary efficacy endpoint, with careful monitoring for cardiac safety.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC, is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering with advanced cancer, particularly metastatic disease. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion entered into an exclusive licensing agreement with Zeneus Pharma Ltd. (now Cephalon, Inc.) for the future commercialization of Myocet in North America. For more information, visit

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
2. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
4. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
9. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
11. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Reports from CDC show ... from one or more chronic health conditions - including ... address some of these diseases, but may not eliminate ... face. While implanted nerve stimulation devices today offer relief, ... which can induce side effects. , To eliminate ...
(Date:12/19/2014)... With only 2 weeks left of 2014, ... Biohit products . The product specials include Buy 1 ... Trade-in Program, and free pipette tips. , Sartorius mLINE ... world. They are ideal for lab technicians performing long ... ,     Full volume range of 0.1 uL to 10 ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Achim Noack has been named global vice president ... position, Noack will assist Jerry Stoller, CEO and president ... and supervise global marketing management and implementation of new ... and experience in the crop protection industry,” says Jerry ... thinking will be a great asset for Stoller Group, ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... 11, 2011 Ardea Biosciences, Inc. (Nasdaq: ... of small-molecule therapeutics for the treatment of serious diseases, ... full-year 2010 financial results. "With approximately $160 ... we are in an excellent financial position," commented Barry ...
... 11, 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... collagenase-based products, today announced its financial results for the fourth ... "2010 was an exciting year for the Company, but ... forward to sales growth of XIAFLEX® in the U.S., as ...
... How fast an intense laser pulse can change the ... Kiel University in the current edition of Nature ... Bauer, Dr. Kai Ronagel and Professor Lutz Kipp from ... colleagues from the University of Kaiserslautern and the University ...
Cached Biology Technology:Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
(Date:11/21/2014)... According to a new market ... RFID, Access Control, Intrusion Detection, Parking Management, Under Vehicle ... Service Geography - Global Forecasts to 2020", published by ... be around $25 Billion in 2014 and is expected ... CAGR of 8.69%. Browse 116 market data ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... In January 2001, the world held its breath when the ... reef and began breaking up in the heart of one ... the Galapagos Islands. At risk were vast numbers ... by Charles Darwin that contributed to his landmark theory of ...
... skull, is estimated to affect one out of every 2,000 ... procedures to correct the problems. One procedure was to make ... of the infant and reshape the skull by breaking the ... incision near the point of the fused skull plates. Now, ...
... Michael Goodisman could be called the Maury Povich of ... the paternity of yellow jackets to study family dynamics ... within a colony, each yellow jacket queen mates with ... insects such as yellow jackets have been described as ...
Cached Biology News:First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4Craniosynostosis minimally invasive surgery holds more promise than old procedure 2Research uncovers the social dynamics of yellow jackets 2Research uncovers the social dynamics of yellow jackets 3Research uncovers the social dynamics of yellow jackets 4
... microPET R4 is the lowest priced, full ... the world. Despite the microPET R4 ... systems in all performance categories; count rate ... set., microPET is a dedicated small animal ...
... offers versatile liquid handling platforms and flexible ... variety of life science applications.The Freedom EVO ... (75, 100, 150 and 200 cm), giving ... that will advance with their application needs. ...
...
... utilizes utilizies CTI Molecular Imaging's proprietary ... resolution, sensitivty, and a large imaging ... flexibility to image multiple mice or ... is a dedicated small animal PET ...
Biology Products: